English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  The prognostic impact of β‐blockers ( BB ) in acute coronary syndrome ( ACS ) patients without heart failure ( HF ) or left ventricular dysfunction is controversial, especially in the postreperfusion era. We sought to determine whether a  BB  therapy before admission for  ACS  has a favorable in‐hospital outcome in patients without  HF , and whether they also reduce 12‐month mortality if still prescribed on discharge.    Methods and Results  The  GULF ‐ RACE  2 (Gulf Registry of Acute Coronary Events‐2) is a prospective multicenter study of  ACS  in 6 Middle Eastern countries. We studied in‐hospital cardiovascular events in patients hospitalized for  ACS  without  HF  in relation to  BB  on admission, and 1‐year mortality in relation to  BB  on discharge. Among the 7903 participants, 7407 did not have  HF , of whom 5937 (80.15%) patients were on  BB . Patients on  BB  tended to be older and have more comorbidities. However, they had a lower risk of in‐hospital mortality, mitral regurgitation,  HF , cardiogenic shock, and ventricular tachycardia/ventricular fibrillation. Furthermore, 4208 patients were discharged alive and had an ejection fraction ≥40%. Among those, 84.1% had a  BB  prescription. At 12 months, they also had a reduced risk of mortality as compared with the non‐ BB  group. Even after correcting for confounding factors in 2 different models, in‐hospital and 12‐month mortality risk was still lower in the  BB  group.    Conclusions  In this cohort of  ACS ,  BB  therapy before admission for  ACS  is associated with decreased in‐hospital mortality and major cardiovascular events, and 1‐year mortality in patients without  HF  or left ventricular dysfunction if still prescribed on discharge.

journal of the american heart association

β‐Blocker Therapy Prior to Admission for Acute Coronary Syndrome in Patients Without Heart Failure or Left Ventricular Dysfunction Improves In‐Hospital and 12‐Month Outcome: Results From the GULF‐RACE 2 (Gulf Registry of Acute Coronary Events‐2)